All In Biotech

Drug Trial Radar · NCT07937696

A Vaccine (Nous-209) for the Reduction of Colorectal Lesion Size in Patients With Lynch Syndrome

A Phase II Clinical Trial of Nous-209 for Colorectal Pre-Cancer Immune Interception in Lynch Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

55

Planned (sponsor's estimate)

Start

Apr 27, 2027

Primary completion

Nov 30, 2031

Study completion Jul 31, 2032

Sponsor

Sponsor type
NIH
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well a vaccine called Nous-209 works in reducing the size of abnormal area of tissue growth or polyps (colorectal lesions) in patients with Lynch syndrome. When patients have Lynch syndrome, errors in the genetic information inside cells are not properly corrected. When that happens, the cells produce new proteins called neoantigens. Nous-209 is a vaccine with man-made copies of neoantigens combined with viral vectors. Neoantigens are new proteins that form inside tumor cells when certain mutations occur inside them. The body's immune system recognizes these proteins as foreign and generates a response against the tumor cell that produced the neoantigen. Giving the Nous-209 vaccine may be able to reduce the size of existing colorectal lesions (polyps) that were 5 to 15 mm in diameter at the time of patients' first colonoscopy or flexible sigmoidoscopy.

Conditions

  • Colorectal Carcinoma
  • EPCAM Lynch Syndrome
  • Lynch Syndrome
  • MLH1 Lynch Syndrome
  • MSH2 Lynch Syndrome
  • MSH6 Lynch Syndrome
  • PMS2 Lynch Syndrome

Interventions

  • Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSPBiological

    Given IM

  • Biopsy ProcedureProcedure

    Undergo tissue biopsies

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • ColonoscopyProcedure

    Undergo colonoscopy

  • MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSPBiological

    Given IM

  • SigmoidoscopyProcedure

    Undergo flexible sigmoidoscopy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participant-level response rateTime frame: Baseline to week 16

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • University of Kansas Cancer Center

    Kansas City, Kansas

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • UT MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.